Tags

Type your tag names separated by a space and hit enter

[Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
Nefrologia. 2008; 28(2):168-73.N

Abstract

INTRODUCTION

Aluminium binder has been ill-advised, but his use remain applicable in the clinique practice in very seleccionated and particular patients. The repercussion of prolonged treatment with low doses of aluminium phosphate-binders in haemodialysis was studied. The haemodialysis unit had a double osmosis inverse and the aluminium levels in haemodialysis liquid was less than 2 micrograms/liter.

METHODS

41 patients of the 295 on haemodialysis received aluminium phosphate-binders since the 2005 January to the 2007 November. The mean time of treatment was 17.8 months, and the doses was 3.9 tablets day (mean of 463 grams in the studied period). The association of low doses of aluminium phosphate-binders permitted a better control of phosphorus (6.8 to 4.8 mg/dl; p<0.0001), with a reduction of the others phosphate-binders: sevelamer (10.4 a 8 tablets/day; p<0.0001) and calcium phosphate-binders (4.6 to 3.1 tablets/day; p<0.0001). The serum aluminium increased after the aluminium treatment (6.8 to 13.8 mcg/l; p<0.0001), and no toxicity indirect signs were observed on CMV, haemoglobin, none PTH. Five patients (12.1%) reached aluminium serum levels higher 20 mcg/l, and none reached the 40 mcg/l.

CONCLUSIONS

The aluminium phosphate-binders were effective, economical and, now, with an apparent better security profile than in a previous time, but it is very important to be careful with this use and to follow a vigilance strict on patients and haemodialysis liquid.

Authors+Show Affiliations

Hospital Perpetuo Socorro, Alicante. lola@olemiswebs.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

spa

PubMed ID

18454706

Citation

Arenas, Maria D., et al. "[Use of the Aluminum Phosphate-binders in Hemodialysis in the Ultrapure Water Era]." Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia, vol. 28, no. 2, 2008, pp. 168-73.
Arenas MD, Malek T, Gil MT, et al. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era]. Nefrologia. 2008;28(2):168-73.
Arenas, M. D., Malek, T., Gil, M. T., Moledous, A., Núñez, C., & Alvarez-Ude, F. (2008). [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era]. Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia, 28(2), 168-73.
Arenas MD, et al. [Use of the Aluminum Phosphate-binders in Hemodialysis in the Ultrapure Water Era]. Nefrologia. 2008;28(2):168-73. PubMed PMID: 18454706.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era]. AU - Arenas,Maria D, AU - Malek,T, AU - Gil,M T, AU - Moledous,A, AU - Núñez,C, AU - Alvarez-Ude,F, PY - 2008/5/6/pubmed PY - 2008/9/19/medline PY - 2008/5/6/entrez SP - 168 EP - 73 JF - Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia JO - Nefrologia VL - 28 IS - 2 N2 - INTRODUCTION: Aluminium binder has been ill-advised, but his use remain applicable in the clinique practice in very seleccionated and particular patients. The repercussion of prolonged treatment with low doses of aluminium phosphate-binders in haemodialysis was studied. The haemodialysis unit had a double osmosis inverse and the aluminium levels in haemodialysis liquid was less than 2 micrograms/liter. METHODS: 41 patients of the 295 on haemodialysis received aluminium phosphate-binders since the 2005 January to the 2007 November. The mean time of treatment was 17.8 months, and the doses was 3.9 tablets day (mean of 463 grams in the studied period). The association of low doses of aluminium phosphate-binders permitted a better control of phosphorus (6.8 to 4.8 mg/dl; p<0.0001), with a reduction of the others phosphate-binders: sevelamer (10.4 a 8 tablets/day; p<0.0001) and calcium phosphate-binders (4.6 to 3.1 tablets/day; p<0.0001). The serum aluminium increased after the aluminium treatment (6.8 to 13.8 mcg/l; p<0.0001), and no toxicity indirect signs were observed on CMV, haemoglobin, none PTH. Five patients (12.1%) reached aluminium serum levels higher 20 mcg/l, and none reached the 40 mcg/l. CONCLUSIONS: The aluminium phosphate-binders were effective, economical and, now, with an apparent better security profile than in a previous time, but it is very important to be careful with this use and to follow a vigilance strict on patients and haemodialysis liquid. SN - 0211-6995 UR - https://www.unboundmedicine.com/medline/citation/18454706/[Use_of_the_aluminum_phosphate_binders_in_hemodialysis_in_the_ultrapure_water_era]_ DB - PRIME DP - Unbound Medicine ER -